471
Participants
Start Date
October 31, 2009
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
everolimus
Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
sunitinib
Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
Novartis Investigative Site, Jesus Maria
Novartis Investigative Site, Taipei
Novartis Investigative Site, Woodville
Memorial Sloan Kettering Cancer Center Dept. of MSKCC, New York
Novartis Investigative Site, Berlin
Novartis Investigative Site, Bangkok
Clinical Research Alliance, Lake Success
SUNY - Upstate Medical University Div. of Hematology-Oncology, Syracuse
St. Luke's Hospital and Health Network St Luke's Hospital (2), Bethlehem
VA Maryland Health Care Dept.of GreenbaumCancerCent(7), Baltimore
Novartis Investigative Site, Lleida
Duke University Medical Center Duke, Durham
Levine Cancer Institute Oncology, Charlotte
University Cancer & Blood Center, LLC Dept of NE GCC (2), Athens
Georgia Health Sciences University Dept. of MCG, Augusta
Novartis Investigative Site, Chihuahua City
Summit Cancer Care, Savannah
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando, Orlando
University of Miami SC, Miami
Lynn Cancer Institute, Boca Raton
Novartis Investigative Site, Istanbul
University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile
The West Clinic Dept. of the West Clinic, Memphis
Novartis Investigative Site, Seville
Novartis Investigative Site, Modena
Novartis Investigative Site, Angers
Novartis Investigative Site, Arezzo
Aurora Advanced Healthcare SC, Milwaukee
Novartis Investigative Site, Vandoeuvre-Les-Nancy Cede
Novartis Investigative Site, Lille
Billings Clinic Dept of Billings Clinic(2), Billings
Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3), Maywood
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept.ofNorthwesternMemHospital, Chicago
Novartis Investigative Site, Aschaffenburg
Crescent City Research Consortium, LLC SC, Metairie
Highlands Oncology Group HighlandsOncGrp-Bentonville(2), Fayetteville
University of Oklahoma Health Sciences Center Dept of OHSC, Oklahoma City
Novartis Investigative Site, Paris
East Texas Medical Center Cancer Institute, Tyler
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2), Fort Worth
University of Colorado Dept. of Anschutz Cancer (2), Aurora
Novartis Investigative Site, Napoli
Novartis Investigative Site, Niaosong Township
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3), Salt Lake City
University of California at Los Angeles Dept. of UCLA (3), Los Angeles
Novartis Investigative Site, Weiden
University of Alabama at Birmingham/ Kirklin Clinic Comprehensive CancerCenter (1), Birmingham
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5), La Jolla
Norwalk Hospital Norwlak SC, Norwalk
Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Ctr (2, Washington D.C.
Weinberg Cancer Institute at Franklin Square Hospital, Baltimore
Hackensack University Medical Center DeptofHackensackUniv.MedCtr., Hackensack
Cooper Cancer Center, Voorhees Township
University of North Carolina Dept. of LinbergerCancerCtr(3), Chapel Hill
Novartis Investigative Site, Caba
Novartis Investigative Site, La Plata
Novartis Investigative Site, Rosario
Novartis Investigative Site, San Miguel de Tucumán
Novartis Investigative Site, Rio de Janeiro
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Calgary
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Victoria
Novartis Investigative Site, Toronto
Novartis Investigative Site, Toronto
Novartis Investigative Site, Greenfield Park
Novartis Investigative Site, Montreal
Novartis Investigative Site, Saskatoon
Novartis Investigative Site, Herlev
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Shatin, New Territories
Novartis Investigative Site, Maastricht
Novartis Investigative Site, The Hague
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Daejeon
Novartis Investigative Site, Elche
Novartis Investigative Site, Sabadell
Novartis Investigative Site, Bristol
Novartis Investigative Site, London
Novartis Investigative Site, Nottingham
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY